Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Operating Expenses (2016 - 2025)

Veracyte's Operating Expenses history spans 14 years, with the latest figure at $64.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 13.14% year-over-year to $64.8 million; the TTM value through Dec 2025 reached $304.8 million, up 8.07%, while the annual FY2025 figure was $304.8 million, 8.07% up from the prior year.
  • Operating Expenses for Q4 2025 was $64.8 million at Veracyte, down from $68.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $95.0 million in Q2 2025 and bottomed at -$35.1 million in Q4 2022.
  • The 5-year median for Operating Expenses is $75.6 million (2024), against an average of $71.0 million.
  • The largest annual shift saw Operating Expenses tumbled 144.1% in 2022 before it skyrocketed 297.11% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $79.7 million in 2021, then crashed by 144.1% to -$35.1 million in 2022, then surged by 297.11% to $69.3 million in 2023, then rose by 7.68% to $74.6 million in 2024, then dropped by 13.14% to $64.8 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Operating Expenses are $64.8 million (Q4 2025), $68.3 million (Q3 2025), and $95.0 million (Q2 2025).